Alkermes (ALKS) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 7.59% |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -99.40% |
| Mar 31, 2026 | -396.14% |
| Dec 31, 2025 | -66.38% |
| Sep 30, 2025 | -10.37% |
| Jun 30, 2025 | -3.98% |
| Mar 31, 2025 | -38.28% |
| Dec 31, 2024 | 22.73% |
| Sep 30, 2024 | 99.98% |
| Jun 30, 2024 | -61.73% |
| Mar 31, 2024 | 174.93% |
| Dec 31, 2023 | 36.46% |
| Sep 30, 2023 | 172.16% |
| Jun 30, 2023 | 886.52% |
| Mar 31, 2023 | -35.29% |
| Dec 31, 2022 | -30.08% |
| Sep 30, 2022 | -120.69% |
| Jun 30, 2022 | -1,374.79% |
| Mar 31, 2022 | -60.15% |
| Dec 31, 2021 | 394.18% |
| Sep 30, 2021 | -21,532.84% |